MDManas Kumar DAS

Manas Kumar DAS

*This is an algorithmically generated author record based on publicly available information.

Manas Kumar DAS has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel nano-emulsion cream of casein isolated from raw milk for thermal and acid burn wounds

    by Shivani Shrivastava, Saumya Das, Chanchal Sharma, Archna Singh, Sanjita Das, Manas Kumar Das, Pankaj Kumar Tyagi, Navneet Khurana

    Traditionally, raw cow milk has been employed to treat acid and thermal burns due to its antibacterial, antibiotic, and antifungal properties. It also aids in preventing scarring and alleviating burn-related skin discomfort. This study focuses on evaluating a nanoemulsion cream made from casein extracted from raw cow milk for managing acid and thermal burns. Casein was isolated and used to create 2%, 5%, and 10% w/w nanoemulsion creams. Wistar albino rats were used to induce acid and thermal burns, and the healing progress was monitored by measuring wound contraction and epithelialization period. The results demonstrated significant wound healing effects of the casein creams (p<0.001) in acid burns, with the 10% w/w cream showing the highest epithelization rate in thermal burns. Raw milk also exhibited notable healing properties in acid burns. However, its effectiveness was relatively lower in thermal burns. This study suggests that raw milk and its casein-derived creams could be utilized as first-aid treatments for acid burns, though they may be less effective for thermal burns.


  • Ameliorative Potential of Rosuvastatin on Doxorubicin-induced Cardiotoxicity by Modulating Oxidative Damage in Rats

    by Jayaraman Rajangam, Navaneetha Krishnan S, Narahari N Palei, Shvetank Bhatt, Manas Kumar DAS, Saumya DAS, Krishnapillai Mathusoothanan

    The study aimed to explore the in vivo protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats. Cardiac toxicity was induced by DOXO injection (10 mg/kg, i.p.), once on the 20th day of the experiment. Except for the control rats, all were received DOXO and the study was continued for up to 21 days. The influence of ROSS on acute treatment was analyzed by quantification of cardiac marker enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and liver marker enzymes like aspartate aminotransferase (AST), alanine aminotransferase (ALT) along with the measurement of in vivo antioxidants like superoxide dismutase and catalase. To observe histological changes of myocardial tissue hematoxylin and eosin staining were used. Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p<0.05) and AST, ALT levels to a remarkable extent. Moreover, ROSS administration significantly increased the activities of various in vivo antioxidant levels. From the results, the acute administration of ROSS showed significant cardioprotective property, which was evidenced by a significant reduction of cardiac and liver marker enzymes along with significant improvement of in vivo antioxidant activities. Furthermore the results were supported with histopathological observations. Hence, it can be concluded that cardioprotective potential of ROSS may be through attenuation of oxidative stress by modulating oxidative damage in rats.